Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

287.32 +5.53 (+1.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,461,481
Open 280.17
Bid (Size) 285.55 (1)
Ask (Size) 288.20 (1)
Prev. Close 281.79
Today's Range 279.42 - 287.86
52wk Range 176.36 - 293.17
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Amphastar Pharmaceuticals Stock Scores Composite Rating Climb To 96
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before. 
Via Investor's Business Daily
Kura Oncology Stock Scores Rising Relative Strength
On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier. 
Via Investor's Business Daily

Performance

YTD
+29.12%
+29.12%
1 Month
+6.65%
+6.65%
3 Month
+7.95%
+7.95%
6 Month
+30.84%
+30.84%
1 Year
+42.09%
+42.09%

More News

Read More
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92
Via Investor's Business Daily
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Via Investor's Business Daily
Why Jim Cramer Prefers Devon Energy Over EOG Resources
Via Benzinga
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
Via Investor's Business Daily
Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money
Via InvestorPlace
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade
Via Investor's Business Daily
Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?
Via Investor's Business Daily
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
Via Benzinga
Expert Ratings for Vertex Pharmaceuticals
Via Benzinga
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing
Via Investor's Business Daily
7 of the Hottest ETFs to Buy Right Now
Via InvestorPlace
Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Pacira Pharmaceuticals Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark
Via Investor's Business Daily
Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82
Via Investor's Business Daily
Vertex Pharma Gains FDA Breakthrough Therapy Designation For Kidney Disease Drug
Via Benzinga
Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
From Vertex Pharmaceuticals Incorporated
Via Business Wire
7 Oversold Stocks to Buy Right Now
Via InvestorPlace
Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
Via Benzinga
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.